The estimated Net Worth of Manmeet Singh Soni is at least $549 Million dollars as of 13 October 2023. Mr. Soni owns over 2,976,190 units of Reata Pharmaceuticals Inc stock worth over $512,976,108 and over the last 7 years he sold RETA stock worth over $23,550,186. In addition, he makes $12,612,200 as Chief Financial Officer, Chief Operating Officer, and Executive Vice President at Reata Pharmaceuticals Inc.
Sign up
Mr. Soni RETA stock SEC Form 4 insiders trading
Manmeet has made over 12 trades of the Reata Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,976,190 units of RETA stock worth $4,999,999 on 13 October 2023.
The largest trade he's ever made was buying 2,976,190 units of Reata Pharmaceuticals Inc stock on 13 October 2023 worth over $4,999,999. On average, Manmeet trades about 79,598 units every 40 days since 2017. As of 13 October 2023 he still owns at least 2,976,190 units of Reata Pharmaceuticals Inc stock.
You can see the complete history of Mr. Soni stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Manmeet Soni biography
Manmeet S. Soni CPA serves as Chief Financial Officer, Chief Operating Officer, Executive Vice President of the Company. He served as Senior Vice President and Chief Financial Officer of Alnylam Pharmaceuticals, Inc. from May 2017 until August 2019. From March 2016 to February 2017, Mr. Soni served as the Executive Vice President, Chief Financial Officer, and Treasurer of ARIAD Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, when ARIAD was acquired by Takeda Pharmaceutical Company Limited. Mr. Soni continued as an employee of ARIAD through May 2017. Previously, Mr. Soni served as Chief Financial Officer and Treasurer of Pharmacyclics, Inc., a publicly-held biopharmaceutical company, until its acquisition by AbbVie, Inc. in May 2015, after which he supported AbbVie during the post-acquisition transition through September 2015. He first joined Pharmacyclics in September 2012 as Corporate Controller and was promoted to serve as Principal Accounting and Financial Officer, Treasurer in August 2013, prior to being appointed as Chief Financial Officer and Treasurer in February 2014. Prior to joining Pharmacyclics, Mr. Soni worked at ZELTIQ Aesthetics Inc., a publicly-held medical technology company as Corporate Controller. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers from June 2007 to January 2012 in their Life Science and Venture Capital Group. Prior to that, he worked at PricewaterhouseCoopers India, providing audit and assurance services. Mr. Soni serves as a member of the board of directors of Pulse Biosciences, Inc. and Arena Pharmaceuticals, Inc. Mr. Soni graduated from Hansraj College at Delhi University in India. He is a certified public accountant and completed his Chartered Accountancy from the Institute of Chartered Accountants of India.
What is the salary of Manmeet Soni?
As the Chief Financial Officer, Chief Operating Officer, and Executive Vice President of Reata Pharmaceuticals Inc, the total compensation of Manmeet Soni at Reata Pharmaceuticals Inc is $12,612,200. There are no executives at Reata Pharmaceuticals Inc getting paid more.
How old is Manmeet Soni?
Manmeet Soni is 42, he's been the Chief Financial Officer, Chief Operating Officer, and Executive Vice President of Reata Pharmaceuticals Inc since 2020. There are 13 older and 1 younger executives at Reata Pharmaceuticals Inc. The oldest executive at Reata Pharmaceuticals Inc is Michael D. Wortley, 73, who is the Exec. VP & Chief Legal Officer.
What's Manmeet Soni's mailing address?
Manmeet's mailing address filed with the SEC is C/O SUMMIT THERAPEUTICS INC., 601 BRICKELL KEY DRIVE, SUITE 1000, MIAMI, FL, 33131.
Insiders trading at Reata Pharmaceuticals Inc
Over the last 8 years, insiders at Reata Pharmaceuticals Inc have traded over $176,850,875 worth of Reata Pharmaceuticals Inc stock and bought 8,443,489 units worth $179,313,590 . The most active insiders traders include Holdings A/S Novo, R Kent Jr Mc Gaughy, and Inc Cpmg. On average, Reata Pharmaceuticals Inc executives and independent directors trade stock every 16 days with the average trade being worth of $10,950,893. The most recent stock trade was executed by Andrea Loewen on 14 September 2023, trading 3,175 units of RETA stock currently worth $546,195.
What does Reata Pharmaceuticals Inc do?
reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
What does Reata Pharmaceuticals Inc's logo look like?
Complete history of Mr. Soni stock trades at Alnylam Pharmaceuticals Inc, Arena Pharmaceuticals Inc, Pulse Biosciences Inc, Reata Pharmaceuticals Inc, and Summit Therapeutics Inc
Reata Pharmaceuticals Inc executives and stock owners
Reata Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Manmeet Soni,
Chief Financial Officer, Chief Operating Officer, Executive Vice President -
J. Warren Huff,
Chairman of the Board, President, Chief Executive Officer -
Colin Meyer,
Executive Vice President, Chief Research and Development Officer -
Michael Wortley,
Executive Vice President, Chief Legal Officer -
Dawn Bir,
Executive Vice President, Chief Commercial Officer -
Manmeet Singh Soni,
COO, CFO & Pres -
J. Warren Huff,
Chairman & CEO -
Dr. Colin J. Meyer M.D.,
Exec. VP & Chief Innovation Officer -
Michael D. Wortley,
Exec. VP & Chief Legal Officer -
Dawn Carter Bir,
Exec. VP & Chief Commercial Officer -
Jack Nielsen,
Independent Director -
William McClellan,
Independent Director -
William Rose,
Independent Director -
R. Kent McGaughy,
Independent Director -
Vineet Jindal,
Vice President, Corporate Communications and Strategy -
Martin Edwards,
Independent Director -
Seemi Khan,
Chief Medical Officer -
Andrea Loewen,
Vice President - Global Regulatory Affairs -
Kevin Johnston,
Chief Technical Officer, Vice President -
Steve Harman,
VP & Chief HR Officer -
Dakota Gallivan,
VP & Chief Healthcare Compliance Officer -
Dr. W. Christian Wigley Ph.D.,
Sr. VP & Chief Scientific Officer -
Bhaskar Anand,
VP & Chief Accounting Officer -
William Puffin Partners, L....,
-
Dennis K. Stone,
Director -
Elaine Castellanos,
VP, Chief Accounting Officer -
Holdings A/S Novo,
10% owner -
James Edward Bass,
Director -
James W Jr Traweek,
-
Inc Cpmg,
-
Inc. Abb Vie,
10% owner -
Keith Wayne Ward,
See Remarks -
William Rose Evelyn P.Edwar...,
-
William Puffin Partners, L....,
-
Antal Rohit Cpmg Inc Desai,
-
William Montrose Investment...,
-
William Charles Henry Rose ...,
-
William Puffin Partners, L....,
-
William Estate Of Edward W....,
-
Jason Douglas Wilson,
Executive VP of Operations -
Pharma Llcstapleton Craig R...,
-
Christy J. Oliger,
Director -
Shamim Ruff,
Director -
Bhaskar Anand,
SVP, Chief Accounting Officer -
Steven Ryder,
Director -
Samina Khan,
SVP, Chief Medical Officer -
Rajiv Patni,
EVP, Chief R&D Officer